News & Updates

Safety and efficacy of vitamin B in cancer treatments: A systematic review

29 May 2024

Supplementation with vitamin B may or may not reduce the risk of certain cancers, with varying effects depending on the type of cancer and vitamin B compounds, according to a study.

Safety and efficacy of vitamin B in cancer treatments: A systematic review

29 May 2024

SABR hits efficacy, safety targets for NSCLC with interstitial lung disease

29 May 2024

In the treatment of patients with interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) has met the prespecified acceptability thresholds for both toxicity and efficacy, according to the single-arm, phase II ASPIRE-ILD study.

SABR hits efficacy, safety targets for NSCLC with interstitial lung disease

29 May 2024

Life quality drops then steadily improves after thyroidectomy in DTC patients

28 May 2024

Patients with differentiated thyroid cancer (DTC) may experience a significant decline in health-related quality of life (HR-QoL) 3 months after thyroidectomy, but their HR-QoL will gradually improve and even exceed preoperative QoL by year 5, suggests a study.

Life quality drops then steadily improves after thyroidectomy in DTC patients

28 May 2024

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

28 May 2024 by

After 29 months of minimum follow‐up, nivolumab plus chemotherapy and nivolumab plus ipilimumab continued to demonstrate clinically meaningful overall survival (OS) benefit vs chemotherapy in patients with previously untreated, unresectable, advanced, recurrent, or metastatic oesophageal squamous-cell carcinoma (ESCC), according to results of the global, open-label, phase III CheckMate 648 trial.

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

28 May 2024

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

28 May 2024 by

Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

28 May 2024

Bariatric surgery cuts breast cancer risk in women with obesity

25 May 2024

Bariatric surgery appears to have a protective effect on the risk of breast cancer in women with obesity, especially those with hyperinsulinemia, according to data from the Swedish Obese Subjects (SOS) study.

Bariatric surgery cuts breast cancer risk in women with obesity

25 May 2024

Limit intake of ultra-processed food to prolong life: study

24 May 2024 by

Individuals who regularly eat ultra-processed foods are at greater risk of death, which is driven by causes other than cancer and cardiovascular diseases (CVD), reports a study.

Limit intake of ultra-processed food to prolong life: study

24 May 2024

Prophylactic intranasal IFN-α cuts COVID-19 incidence in cancer patients

20 May 2024 by

Prophylactic interferon-alpha (IFN-α) administered intranasally slashed the incidence of COVID-19 by almost half in a cohort of cancer patients in the C-SMART study.

Prophylactic intranasal IFN-α cuts COVID-19 incidence in cancer patients

20 May 2024

Onvansertib plus chemo shows promise in KRAS-mutant metastatic colorectal cancer

20 May 2024

In the second-line treatment of patients with metastatic colorectal cancer harbouring KRAS mutation, onvansertib combined with FOLIFRI/bevacizumab demonstrates promising clinical activity while having a manageable safety profile, according to the results of a phase Ib study.

Onvansertib plus chemo shows promise in KRAS-mutant metastatic colorectal cancer

20 May 2024

Aspirin may offer protection against GI cancer-related death in H pylori-free individuals

18 May 2024

For people who have successfully undergone Helicobacter pylori-eradication therapy, the use of aspirin does more good than harm, such that the benefit of reduced gastrointestinal (GI) cancer-related mortality outweighs the risk of bleeding-related mortality, according to a study.

Aspirin may offer protection against GI cancer-related death in H pylori-free individuals

18 May 2024

News & Updates

Filter by Specialty:

Specialty:

Safety and efficacy of vitamin B in cancer treatments: A systematic review

Safety and efficacy of vitamin B in cancer treatments: A systematic review

SABR hits efficacy, safety targets for NSCLC with interstitial lung disease

SABR hits efficacy, safety targets for NSCLC with interstitial lung disease

Life quality drops then steadily improves after thyroidectomy in DTC patients

Life quality drops then steadily improves after thyroidectomy in DTC patients

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

CheckMate 648: Nivo + chemo and nivo + ipi continue to improve OS vs chemo in ESCC at 29-month follow-up

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

MAURIS interim safety and efficacy results in “real-world” ES-SCLC patients similar to IMpower133

Bariatric surgery cuts breast cancer risk in women with obesity

Bariatric surgery cuts breast cancer risk in women with obesity

Limit intake of ultra-processed food to prolong life: study

Limit intake of ultra-processed food to prolong life: study

Prophylactic intranasal IFN-α cuts COVID-19 incidence in cancer patients

Prophylactic intranasal IFN-α cuts COVID-19 incidence in cancer patients

Onvansertib plus chemo shows promise in KRAS-mutant metastatic colorectal cancer

Onvansertib plus chemo shows promise in KRAS-mutant metastatic colorectal cancer

Aspirin may offer protection against GI cancer-related death in H pylori-free individuals

Aspirin may offer protection against GI cancer-related death in H pylori-free individuals